Safety · Evidence update
BIA-ALCL evidence update 2026
Updated incidence rates, modern surveillance approaches, and what has changed since the 2019 BIOCELL recall.
April 8, 2026 · Dr. Ayhan Işık Erdal, MD, FACS, FEBOPRAS
The 2019 worldwide recall of Allergan BIOCELL macrotextured implants was the most significant safety event in modern breast implant history. Six years later, the evidence base has matured substantially. Here's what the 2026 updates show.
Modern incidence rates
Updated risk estimates by implant surface:
| Surface | BIA-ALCL lifetime risk (2026 data) | Status |
|---|
| Smooth | Essentially undetectable | Lowest documented risk |
| Microtextured (Siltex) | ~1 in 30,000-50,000 | Available; lower-risk textured |
| Microtextured (SilkSurface) | Very low | Available; finer microtexturing |
| Polyurethane-coated | Very low | Available |
| Macrotextured (BIOCELL) | ~1 in 2,000-3,000 | RECALLED 2019 |
The 2026 updates have refined these estimates with larger registry data. The fundamental risk hierarchy hasn't changed — macrotextured (BIOCELL specifically) was substantially elevated; smooth and modern microtextured surfaces are very low. The shift in modern practice toward smooth and lower-risk microtextured surfaces continues.
What's changed since 2019
Market shift
Smooth-surface round implants now account for approximately 65-70% of new placements globally — meaningful shift from textured-dominant era of 2010-2018. Microtextured remains the standard for anatomical implants (rotation prevention required). Polyurethane-coated retained as European specialty.
Surveillance refinement
High-resolution ultrasound increasingly accepted as alternative to MRI for routine surveillance — more accessible, lower cost, validated in 2024-2026 studies for silicone gel rupture and late-onset seroma detection. MRI remains gold standard but ultrasound is acceptable alternative.
Treatment pathway clarity
En bloc capsulectomy remains standard treatment for confirmed BIA-ALCL — surgical technique unchanged but more plastic surgeons globally now have substantial en bloc experience. Multidisciplinary management protocols for advanced disease have been refined.
Registry maturation
US PROFILE registry, European CONFIRM registry, and Australian/Canadian registries provide better population-level data than 2019 estimates. The data has been broadly consistent with original estimates — no major upward revision of BIOCELL risk; modern surface risk estimates have been refined downward.
What hasn't changed
- BIA-ALCL is still highly treatable when caught early — over 95% cure rate for early-stage disease.
- The cardinal symptom remains late-onset seroma (fluid collection 1+ years post-op).
- FDA, ANSM, MHRA recommendations remain: monitor for symptoms, no automatic prophylactic explant for asymptomatic BIOCELL patients.
- Average latency from implantation to BIA-ALCL diagnosis remains 8-10 years.
- BIA-ALCL is still not breast cancer (it's lymphoma).
- Silicone gel filler is not the cause — surface texturing is the relevant risk factor.
Implications for current patients
| Patient profile | 2026 recommendation |
|---|
| Considering new implants | Choose smooth (round) or microtextured (anatomical); avoid macrotextured |
| Existing BIOCELL implants — asymptomatic | Monitor for symptoms; surveillance imaging; no prophylactic explant required |
| Existing BIOCELL — concerning symptoms | Prompt evaluation: ultrasound + aspiration if seroma, cytology, possibly biopsy |
| Existing modern surfaces (smooth/microtextured) | Standard surveillance for rupture; no specific BIA-ALCL concern |
| Confirmed BIA-ALCL | En bloc capsulectomy + multidisciplinary management |
The 2026 evidence base supports practical confidence: BIA-ALCL is rare with modern implants, treatable when it occurs, and surveillance protocols are well-established. The shift toward lower-risk surfaces in modern practice continues to drive reduction in absolute population-level BIA-ALCL incidence.
Frequently asked questions
Has BIA-ALCL incidence changed since the 2019 BIOCELL recall?
Yes — substantially. With BIOCELL macrotextured implants withdrawn from market, new BIA-ALCL cases attributable to BIOCELL are essentially eliminated for patients who never received BIOCELL. Existing BIOCELL patients continue to face their established risk (~1 in 2,000-3,000 lifetime). Modern smooth and microtextured implant patients have very low BIA-ALCL incidence in current data. The total incidence in the modern implant population is meaningfully lower than 2018-pre-recall era.
Should I worry about BIA-ALCL with my modern implants?
For smooth-surface implants: essentially undetectable in current data. For microtextured (Mentor Siltex, Motiva SilkSurface, etc.): 1 in 30,000-100,000 lifetime risk depending on specific texture. The absolute risk with modern surfaces is low. Continue routine surveillance per FDA recommendations (MRI or ultrasound every 2-3 years for silicone gel rupture detection); BIA-ALCL evaluation triggered by symptoms (late-onset seroma, asymmetry, palpable masses) rather than scheduled testing.
Has the en bloc treatment changed?
En bloc capsulectomy remains the standard treatment for confirmed BIA-ALCL. The technique has not fundamentally changed but surgical experience has grown — more plastic surgeons globally now have en bloc experience. Treatment outcomes remain excellent for early-stage disease (>95% cure rate). Multidisciplinary management (plastic surgery + oncology + hematology) for advanced disease has been refined.
Are there new diagnostic tools?
High-resolution ultrasound has become more widely accepted for surveillance — increasingly used as alternative or first-line to MRI for late-onset seroma evaluation. Cytology techniques have refined. CD30+ ALK-negative pattern remains the diagnostic histopathology. Improved registries (US PROFILE registry, European CONFIRM registry) provide better population-level data than prior estimates.
What happens if I have older BIOCELL implants for >10 years?
Cumulative BIA-ALCL risk with BIOCELL increases with implant duration. Patients with 10+ years of BIOCELL implants have higher cumulative exposure than recent recipients. FDA, ANSM, MHRA recommendations remain: monitor for symptoms, routine surveillance imaging, prompt evaluation if concerning symptoms develop. Elective explant for personal reassurance is supported. Most BIOCELL patients remain asymptomatic; the absolute risk remains under 1 in 2,000.
Related references